More on EWTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-35.9% Growth)
- Ratings (8.0 Score)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Edgewise Therapeutics Inc. (NQ:EWTX)
Delayed: 39.31 -0.68 (1.7%)
Prev. Close $39.99  
Open$39.91 
52 Wk High$ 
52 Wk Low$ 
Day High$39.91 
Day Low$38.91 
P/E N/A  
EPS$ 
Volume911,113 

Friends, Peers and Foes (?): ABBV, AMGN, ARGX, ARWR, AVTX (more...)

Oct 16, 2026 02:50 AM William Blair Starts Edgewise Therapeutics (EWTX) at Outperform
Oct 14, 2026 07:16 AM H.C. Wainwright Reiterates Buy Rating on Edgewise Therapeutics (EWTX)
Oct 8, 2026 08:01 AM Edgewise Therapeutics starts Phase 2 heart failure trial of EDG-15400
Oct 8, 2026 08:00 AM Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Oct 2, 2026 04:47 PM Form 4 Edgewise Therapeutics, For: Oct 01 Filed by: Fox Jonathan C
Oct 1, 2026 08:00 AM Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Sep 22, 2026 07:01 AM Edgewise shares preclinical data on EDG-7500 for heart condition
Sep 22, 2026 07:00 AM Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Sep 21, 2026 07:35 AM Edgewise Therapeutics (EWTX) PT Raised to $57 at H.C. Wainwright
Sep 21, 2026 05:57 AM Edgewise Therapeutics Inc. (EWTX) 2K contracts of September 45 and October 50 calls active
View All Articles

Entities mentioned with EWTX

View All Entities